上客户端，和病友交流
点击下载
返回
淋巴瘤
Jeffrey Zonder M.D.

Jeffrey Zonder M.D.

内科
Karmanos cancer center

擅长疾病

临床新药咨询

通过咨询找到适合自己的药物

专家会诊咨询

专业、及时的一对一咨询

如果您的问题未能解决，您还可以选择：

医学顾问

极速问诊

2万名名医
7*24小时为您匹配
1对1

找专家

肿瘤专科专家
对症找医专科专治

专家介绍

2015-06-17 16:051898
 ·         Gender

·         Male

·         Multidisciplinary Team(s)

·         Hematologic (Malignant) 

·         Department/Research Program(s)

·         Department of Oncology 

·         Cancer Type(s)

·         Multiple Myeloma 
Amyloidosis 
Non-Hodgkin's Lymphoma 
Leukemia 
Plasmacytoma 

·         Contact Info

·         Email:
zonderj@karmanos.org

 

来自 <http://www.karmanos.org/physicians/Jeffrey-Zonder?Disease=73&PageIndex=0&SortDirection=1>

 

·         Education

·         Fellowship
Hematology/oncology Fellow, Wayne State University, Detroit Medical Center, Detroit, MI
Fellowship
Hematology/oncology Chief Fellow, Wayne State University, Detroit Medical Center, Detroit, MI
Medical School
Wayne State University School of Medicine
1995
Residency
Primary Care Internal Medicine Residency Program, Strong Memorial Hospital, Rochester, NY
1998

·         Professional Memberships/Associations

·         American Society of Hematology 
American Society of Clinical Oncology 
Southwest oncology Group, Multiple Myeloma and Special Populations Committees 

·         Board Certifications

·         Michigan State and New York State License
American Board of Internal Medicine
American Board of Internal Medicine - Oncology

·         Clinical Interests

·         Hematology Oncology 

·         Research Interests

·         Investigation of new drug application for white cell disorders 

·         Profile

·         Dr. Zonder has special interest in multidisciplinary care of patients with Multiple Myeloma, as well as other hematologic cancers.In addition, he is focused on the investigation of therapies for Multiple Myeloma.

·         Awards

·         2007 Wayne State University Division of Hematology-Oncology, Hematology Teaching Attending of the Year
2005 Teaching Award, Wayne State University School of Medicine

·         Publications

·         A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma.Blood. 2011 Dec 19. [Epub ahead of print] Authors: Zonder JA, Mohrbacher AF, Singhal S, van Rhee F, Bensinger WI, Ding H, Fry J, Afar DE, Singhal AK
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.J Clin Oncol. 2011 Nov 10;29(32):4243-9. Epub 2011 Oct 11. Authors: Richardson PG, Wolf J, Jakubowiak A, Zonder J, Lonial S, Irwin D, Densmore J, Krishnan A, Raje N, Bar M, Martin T, Schlossman R, Ghobrial IM, Munshi N, Laubach J, Allerton J, Hideshima T, Colson K, Poradosu E, Gardner L, Sportelli P, Anderson KC.
Dermatological complications following initiation of lenalidomide in a patient with chronic lymphocytic leukaemia. Intern Med J. 2011 Mar;41(3):286-8. doi: 10.1111/j.1445-5994.2011.02426.x. Authors: Tageja N, Giorgadze T, Zonder J.
Cancer Patient Fracture evaluation (CAFE) Investigators.Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial. Lancet Oncol. 2011 Mar;12(3):225-35. Epub 2011 Feb 16. Authors: Berenson J, Pflugmacher R, Jarzem P, Zonder J, Schechtman K, Tillman JB, Bastian L, Ashraf T, Vrionis F;
Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a reandomized Southwest oncology Group trial (S0232). Blood. 2010 Dec 23;116(26):5838-41. Epub 2010 Sep 27. Authors: Zonder JA, Crowlet J, Hussein MA, Bolejack V, Moore DF Sr, Whittenberger BF, Abidi MH, Durie BG, Barlogie B.

 

1. 添加医学顾问微信，扫描☟二维码

2. 备注【癌种】进病友群

扫描预约专家问诊

专家科普

同类全球会诊
合作伙伴：